SEC Form 4 · accession 0001437749-17-014288
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Edwardson
Officer — Chief Operations Officer
Period of report
Aug 7, 2017
Accepted (ET)
Aug 9, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 7, 2017 | S | 22,371 | $17.7002 | D | 102,644 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported for the sales on August 7, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.70 to $17.75 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.